General Information
Brivaracetam Impurities and Brivaracetam
Daicel Pharma synthesizes Brivaracetam impurities of exceptional quality, such as Brivaracetam (alfa R, 4R)-Isomer (DS-2), Brivaracetam (Alfa R, 4S)-Isomer (Enantiomer), Brivaracetam (alfa S, 4S)-Isomer (DS-1), Brivaracetam EP Impurity-D,Brivaracetam methyl ester (2S,4R) Isomer, and so on. These impurities are crucial to assess the purity, reliability, and safety of Brivaracetam, an active pharmaceutical ingredient. Besides, Daicel Pharma provides custom synthesis of Brivaracetam impurities to meet clients’ demands for delivery worldwide.
Brivaracetam [CAS: 357336-20-0] is an anticonvulsant medication in combination with other drugs to treat partial-onset seizures. This orally available drug is a derivative of levetiracetam.
Brivaracetam: Use and Commercial Availability
Brivaracetam is an anticonvulsant similar in structure to levetiracetam. It treats localization-related epilepsies and a broader spectrum of epileptic disorders. The trade name for Brivaracetam is Briviact.
Brivaracetam Structure and Mechanism of Action 
The chemical name of Brivaracetam is (αS,4R)-α-Ethyl-2-oxo-4-propyl-1-pyrrolidineacetamide. Its chemical formula is C11H20N2O2, and its molecular weight is approximately 212.29 g/mol.
Brivaracetam has an affinity for synaptic vesicle protein 2A (SV2A) in the brain leading to an anticonvulsant effect. But, its mechanism of action is not known.
Brivaracetam Impurities and Synthesis
Impurities in Brivaracetam are organic impurities, inorganic impurities, and residual solvents. Organic impurities may include related substances formed during the synthetic process1, degradation products due to heat, light, or moisture, and impurities from starting materials. Inorganic impurities are metals or other inorganic substances that may arise during manufacturing. Residual solvents may also be present in the manufacturing process. They should be monitored and controlled within acceptable limits and regulatory guidelines during drug development.
Daicel Pharma offers a Certificate of Analysis (CoA) for Brivaracetam impurity standards, such as as Brivaracetam (alfa R, 4R)-Isomer (DS-2), Brivaracetam (Alfa R, 4S)-Isomer (Enantiomer), Brivaracetam (alfa S, 4S)-Isomer (DS-1), Brivaracetam EP Impurity-D,Brivaracetam methyl ester (2S,4R) Isomer, and so on, generated from an analytical facility compliant with cGMP standards. The CoA includes a comprehensive characterization report comprising data from techniques like 1H NMR, 13C NMR, IR, MASS, and HPLC purity2. Furthermore, on request, we can provide additional data like 13C-DEPT and CHN. Daicel Pharma can prepare unknown Brivaracetam impurities or degradation products. A complete characterization report accompanies every delivery.